Group 1 - The core point of the article is that the China National Medical Products Administration has approved the marketing application for the new drug, Weishiping, for the treatment of moderate to severe active ulcerative colitis in adult patients who have inadequate response, loss of response, or intolerance to traditional therapies or biological agents [1] Group 2 - The approval signifies a significant advancement in treatment options for ulcerative colitis patients in China [1] - The drug is specifically targeted at adult patients with moderate to severe conditions, indicating a focused approach to addressing a critical health issue [1] - This development may enhance the company's position in the gastrointestinal therapeutic market [1]
云顶新耀：国家药品监督管理局已批准维适平新药上市申请